Fairfax Family Practice Residency, Fairfax, Virginia.
Virginia Commonwealth University, Richmond.
JAMA. 2021 Mar 9;325(10):962-970. doi: 10.1001/jama.2021.1117.
Lung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease. The most important risk factor for lung cancer is smoking. Increasing age is also a risk factor for lung cancer. Lung cancer has a generally poor prognosis, with an overall 5-year survival rate of 20.5%. However, early-stage lung cancer has a better prognosis and is more amenable to treatment.
To update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the accuracy of screening for lung cancer with low-dose computed tomography (LDCT) and on the benefits and harms of screening for lung cancer and commissioned a collaborative modeling study to provide information about the optimum age at which to begin and end screening, the optimal screening interval, and the relative benefits and harms of different screening strategies compared with modified versions of multivariate risk prediction models.
This recommendation statement applies to adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
The USPSTF concludes with moderate certainty that annual screening for lung cancer with LDCT has a moderate net benefit in persons at high risk of lung cancer based on age, total cumulative exposure to tobacco smoke, and years since quitting smoking.
The USPSTF recommends annual screening for lung cancer with LDCT in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation) This recommendation replaces the 2013 USPSTF statement that recommended annual screening for lung cancer with LDCT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.
肺癌是美国第二常见的癌症和癌症死亡的主要原因。2020 年,估计有 228820 人被诊断患有肺癌,135720 人死于该疾病。肺癌最重要的危险因素是吸烟。年龄增长也是肺癌的一个危险因素。肺癌的总体预后较差,总体 5 年生存率为 20.5%。然而,早期肺癌的预后较好,更易于治疗。
为了更新其 2013 年的建议,美国预防服务工作组(USPSTF)委托对低剂量计算机断层扫描(LDCT)筛查肺癌的准确性以及肺癌筛查的益处和危害进行了系统评价,并委托合作建模研究提供有关最佳起始和结束筛查年龄、最佳筛查间隔以及与多变量风险预测模型的修改版本相比不同筛查策略的相对益处和危害的信息。
本建议声明适用于年龄在 50 至 80 岁之间、有 20 包年吸烟史且目前仍在吸烟或在过去 15 年内已戒烟的成年人。
USPSTF 得出结论,根据年龄、总累计吸烟暴露量和戒烟年限,使用 LDCT 对肺癌高危人群进行年度筛查,肺癌死亡率适度降低,肺癌死亡率适度降低。
USPSTF 建议对有 20 包年吸烟史且目前仍在吸烟或在过去 15 年内已戒烟的 50 至 80 岁成年人进行 LDCT 肺癌年度筛查。一旦患者停止吸烟 15 年或出现严重限制预期寿命或进行根治性肺癌手术的能力或意愿的健康问题,应停止筛查。(B 级建议)本建议取代了 2013 年 USPSTF 的声明,即建议对有 30 包年吸烟史且目前仍在吸烟或在过去 15 年内已戒烟的 55 至 80 岁成年人进行 LDCT 肺癌年度筛查。